Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273660 | 0.85 | MAPT (0.49) | MEN1KMT2AMAPTGFERSMN1; SMN2 | |
| SCHEMBL13099171 | 0.85 | USP2 (0.52) | MEN1KMT2AMAPTGFERSMN1; SMN2 | |
| SCHEMBL13099125 | 0.84 | ALDH1A1 (0.51) | MEN1KMT2AMAPTGFERSMN1; SMN2 | |
| SCHEMBL6132324 | 0.84 | HDAC3 (0.43) | MEN1KMT2AMAPTGFERSMN1; SMN2 | |
| SCHEMBL6132697 | 0.83 | SIRT2 (0.45) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6374849 | 0.82 | HDAC3 (0.44) | MEN1KMT2AMAPTSMN1; SMN2HDAC8 | |
| SCHEMBL6380498 | 0.81 | HTT (0.45) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6132402 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AMAPTSMN1; SMN2HDAC8 | |
| SCHEMBL6373882 | 0.78 | USP2 (0.47) | MEN1KMT2AMAPTSMN1; SMN2USP2 | |
| SCHEMBL6379350 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AMAPTSMN1; SMN2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | GSK3B 4693/4885MEN1 995/4885KMT2A 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.